野村 弘行

Medicine & Life Sciences

1. Endometrial Neoplasms 100%
2. Ovarian Neoplasms 60%
3. Neoplasms 36%
4. Ovarian Epithelial Carcinoma 36%
5. Carboplatin 28%
6. Paclitaxel 24%
7. Irinotecan 20%
8. Fallopian Tubes 19%
9. Uterine Neoplasms 19%
10. Drug Therapy 19%
11. Japan 19%
12. Carcinoma 18%
13. Hereditary Nonpolyposis Colorectal Neoplasms 18%
14. DNA Mismatch Repair 17%
15. Progression-Free Survival 17%
16. Genes 16%
17. Neoplasm Metastasis 15%
18. Lymph Nodes 15%
19. MicroRNAs 15%
20. Uterine Cervical Neoplasms 14%
21. Mutation 14%
22. Platinum 14%
23. Cisplatin 12%
24. taxane 12%
25. Endometrial Hyperplasia 12%
26. Carcinogenesis 11%
27. Therapeutics 11%
28. Peutz-Jeghers Syndrome 10%
29. Narrow Band Imaging 10%
30. Carcinosarcoma 10%
31. Ovary 10%
32. Docetaxel 10%
33. Sarcoma 10%
34. liposomal doxorubicin 10%
35. Epigenomics 9%
36. Breast Neoplasms 9%
37. Biomarkers 9%
38. Survival 9%
39. Hysteroscopy 9%
40. DNA 9%
41. Choriocarcinoma 9%
42. Adjuvant Chemotherapy 8%
43. Germ-Line Mutation 8%
44. Lymph Node Excision 8%
45. Endometrioid Carcinoma 8%
46. Sentinel Lymph Node 8%
47. Microsatellite Instability 8%
48. Salpingo-oophorectomy 8%
49. Safety 7%
50. Bevacizumab 7%